Leap Investments’s Kyntra Bio KYNB Stock Holding History

Leap Investments’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-679	Closed	-$728K	–	428
2019 Q4	$728K	Buy	+679	New	+$693K	0.34%	92

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Leap Investments's KYNB Position: Q1 2020 in Review

Leap Investments sold out of Kyntra Bio (KYNB) in Q1 2020, closing a stake of 679 shares — an estimated $728K sold.

Leap Investments first reported a position in KYNB in Q4 2019 and held it in 1 quarter. The position peaked at $728K in Q4 2019. 187 funds tracked by Wall St. Rank hold KYNB as of Q1 2020.

Leap Investments reported no remaining Kyntra Bio position as of Q1 2020 after selling out during the quarter.
Leap Investments sold 679 Kyntra Bio shares in Q1 2020, an estimated $728K.
Leap Investments first reported a position in Kyntra Bio in Q4 2019 and held it in 1 quarter.
Leap Investments's Kyntra Bio position peaked at $728K in Q4 2019.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2020.

Based on Leap Investments's 13F filing for Q1 2020, filed 15 May 2020.